Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung CancerLecia V. Sequist, D. Ross Camidge, Joel W. Neal et al.|New England Journal of Medicine|2015Cited by 664
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01Toshio Shimizu, Rebecca S. Heist, Jacob Sands et al.|Journal of Clinical Oncology|2023Cited by 168
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or ChemotherapyKai He, Ticiana Leal, David Berz et al.|Journal of Thoracic Oncology|2023Cited by 38
CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunityRamin Salehi‐Rad, Steven M. Dubinett, Raymond J. Lim et al.|Journal for ImmunoTherapy of Cancer|2023Cited by 30
Characteristics of a <i>CCL21</i> Gene–Modified Dendritic Cell Vaccine Utilized for a Clinical Trial in Non–Small Cell Lung CancerMichael S. Oh, Bin Liu, Camelia Dumitras et al.|Molecular Cancer Therapeutics|2024Cited by 10